Dermatology and Therapy最新文献

{"title":"Treat-to-Target in Clinical Practice: Evaluating Real-World Achievement Rates Against Consensus Guidelines for Atopic Dermatitis.","authors":"Zhao Wang, Luyue Zhang, Ruitao Fan, Jing Shi, Miao Qin, Shijiao Xu, Songmei Geng","doi":"10.1007/s13555-025-01508-w","DOIUrl":"10.1007/s13555-025-01508-w","url":null,"abstract":"<p><strong>Introduction: </strong>Treat-to-target (T2T) strategies have been adopted in atopic dermatitis (AD) management, which defines specific moderate/acceptable and optimal targets for reducing disease severity. However, real-world evidence on the achievement rates of these targets remains limited.</p><p><strong>Methods: </strong>This prospective observational study enrolled patients with moderate-to-severe AD without treatment protocol modifications. Disease severity was longitudinally assessed using 5-point Patient Global Impression of Severity (PGIS-5), Peak Pruritus Numerical Rating Scale (pp-NRS), Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Body Surface Area (BSA), Eczema Area and Severity Index (EASI), and Scoring Atopic Dermatitis (SCORAD) at baseline and weeks 2, 4, 8, and 16. Treatment responses were compared against two established T2T frameworks: the T2T consensus (de Bruin-Weller et al.) and Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations (Silverberg et al.). Target feasibility was evaluated through achievement rates, with thresholds calibrated to balance timely clinical response.</p><p><strong>Results: </strong>Sixty-one patients with moderate-to-severe AD were enrolled. All outcomes measured showed significant improvement over the 16-week observation period. SCORAD50, EASI50, pp-NRS reduction ≥ 3/4, and DLQI reduction ≥ 4 demonstrated appropriate moderate target feasibility. SCORAD75, EASI75/90, pp-NRS ≤ 1, BSA ≤ 2%, and DLQI 0/1 were suitable as optimal targets. Percentage improvements of EASI and SCORAD were more reliable than absolute values. Current targets for PGIS-5 (reduction ≥ 1), POEM (reduction ≥ 4), and BSA (50% improvement) in the moderate category and PGIS-5 ≤ 2 and POEM ≤ 7 in the optimal category may require stricter criteria.</p><p><strong>Conclusion: </strong>Our finding reflects the real-world achievement rate of the current T2T consensus, suggesting that higher thresholds may be warranted in future refinements of T2T strategies.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2897-2910"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.","authors":"Katherine Sanchez, Hanna Englander, Lana Salloum, Samantha Gregoire, Ursula Biba, Sherry Ershadi, Arash Mostaghimi","doi":"10.1007/s13555-025-01517-9","DOIUrl":"10.1007/s13555-025-01517-9","url":null,"abstract":"<p><p>Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss on the scalp, face, and body, affecting approximately 2% of the global population. Current treatments, including topical corticosteroids, topical immunotherapies, and systemic immunosuppressants, often demonstrate inconsistent efficacy and raise concerns about long-term safety, emphasizing the need for safer and more effective therapies. Janus kinase (JAK) inhibitors have emerged as a promising treatment option, offering a targeted approach by addressing the immune-mediated mechanisms driving hair follicle destruction in AA. Recent clinical advances have led to FDA approval of three JAK inhibitors-baricitinib, ritlecitinib, and deuruxolitinib-based on pivotal trials showing significant hair regrowth. Baricitinib has demonstrated durable efficacy, with 35-40% of patients achieving a Severity of Alopecia Tool (SALT) score ≤ 20 at 36 weeks. Ritlecitinib similarly reported 23% of patients achieving a SALT score ≤ 20 at week 24. Deuruxolitinib has also shown efficacy with 31% of patients achieving a SALT score ≤ 20 at 24 weeks. Off-label use of JAK inhibitors like tofacitinib and ruxolitinib have also demonstrated efficacy in limited studies. This review aims to consolidate and summarize the latest clinical evidence and trial data on JAK inhibitors for AA, providing an up-to-date resource for clinicians and researchers to guide evidence-based management and optimize therapeutic outcomes.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2749-2764"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study.","authors":"April Armstrong, Bruce Strober, Paolo Gisondi, Kate K Orroth, Myriam Cordey, Shia T Kent, Cynthia Deignan, Shauna Jardon, Rohini K Hernandez, M Alan Brookhart, Linda Stein Gold","doi":"10.1007/s13555-025-01466-3","DOIUrl":"10.1007/s13555-025-01466-3","url":null,"abstract":"<p><strong>Introduction: </strong>Many patients with psoriasis remain on topical therapy despite meeting criteria for systemic therapy. Our objective was to estimate the effect of earlier initiation of apremilast on attaining body surface area (BSA) treatment targets in patients with psoriasis in a real-world setting.</p><p><strong>Methods: </strong>This retrospective cohort study conducted in the OM1 database analyzed patients with psoriasis and a BSA value between ≥ 1 and ≤ 10% (on index date) who had initiated apremilast or a topical treatment. Relative risks were used to compare achieved BSA targets across treatment groups. Confounding, selection bias, and missing data may have been present, but measures were taken to limit their impact.</p><p><strong>Results: </strong>Of 3589 apremilast initiators, 2073 (57.8%) initiated early (≤ 6 months after index date) and 1516 (42.2%) initiated late (> 6 months); separately, 9777 patients initiated their second or later topical treatment (topical users). Compared with early initiators, late initiators had higher BSA values at treatment initiation. Early apremilast initiators were more likely than topical users to achieve BSA ≤ 1% or ≥ 75% improvement in BSA (BSA-75) at 6 and 12 months after treatment initiation: for early apremilast initiators, the relative risks of achieving BSA ≤ 1% and BSA-75 compared with topical users were 1.54 (95% confidence interval [CI]: 1.27, 1.87) and 1.52 (95% CI: 1.21, 1.89), respectively, at 6 months, and 1.49 (95% CI: 1.23, 1.80) and 1.50 (95% CI: 1.22, 1.85), respectively, at 12 months.</p><p><strong>Conclusions: </strong>Earlier initiation of apremilast, an oral systemic treatment, was associated with lower cumulative disease burden and increased likelihood of attaining BSA goals compared with topical users.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2911-2923"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustainability in Cosmetic Dermatology: Moving Toward an Ecologically Responsible Future.","authors":"Diala Haykal, Frédéric Flament, Christopher Rowland Payne, Sergio Schalka, Michel Philippe, Olivier Rolland, Pascale Mora, Hugues Cartier, Brigitte Dréno","doi":"10.1007/s13555-025-01488-x","DOIUrl":"10.1007/s13555-025-01488-x","url":null,"abstract":"<p><p>Sustainability in cosmetic dermatology is becoming a pivotal aspect of modern clinical practice, aligning with global environmental and public health objectives. This commentary explores the ecological impact of dermatological procedures and products, emphasizing the necessity of integrating sustainable practices to mitigate environmental harm. Key focus areas include reducing carbon footprint through energy-efficient clinics, ethical sourcing of ingredients, eco-friendly packaging, and the adoption of circular economy principles to minimize waste. Additionally, technological advancements, such as artificial intelligence (AI) and blockchain, are transforming sustainability in dermatology by optimizing resource allocation, enhancing transparency, and reducing clinical waste. Regulatory policies and industry standards are also evolving to support environmentally responsible practices. Embedding sustainability into dermatology practice contributes not only to environmental goals but also to the long-term resilience and adaptability of clinics in a shifting regulatory and consumer landscape. By fostering innovation, ethical responsibility, and regulatory compliance, sustainability initiatives in cosmetic dermatology contribute to a more resilient, health-oriented future for both patients and the planet.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2687-2701"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Risk in Vitiligo: No Evidence of Increased Prevalence-A Systematic Review and Meta-analysis.","authors":"Alzahra A Mohammed, Anna S Lengyel, Fanni A Meznerics, István Szondy, Anna Walter, Benedek Nagy, Zsófia Csábi, András Bánvölgyi, Norbert Kiss, Péter Hegyi, Zsuzsanna Kurgyis, Lajos V Kemény","doi":"10.1007/s13555-025-01520-0","DOIUrl":"10.1007/s13555-025-01520-0","url":null,"abstract":"<p><strong>Introduction: </strong>Vitiligo, a chronic depigmenting disorder affecting 1-2% of the global population, is caused by immune-mediated melanocyte destruction. While its pathogenesis is multifactorial, the relationship between vitiligo and malignancy risk remains controversial. Some studies suggest an increased cancer risk, while others propose a potential protective effect, particularly against skin cancers. This study provides a comprehensive evaluation of malignancy risks in patients with vitiligo.</p><p><strong>Methods: </strong>This systematic review and meta-analysis followed PRISMA 2020 guidelines and was registered with PROSPERO (CRD42023483130). A comprehensive search was conducted across Medline, EMBASE, and Cochrane databases. Studies reporting hazard ratios for malignancy incidence in patients with vitiligo were included. Data extraction and risk of bias assessment were performed using the Cochrane ROBINS-E tool.</p><p><strong>Results: </strong>Of 7753 records identified, 6378 remained after duplicates were removed, and 12 studies were included in the final review. Quantitative analysis was performed on six studies. The combined sample comprised 3,267,951 participants, including 289,322 patients with vitiligo. Three meta-analyses were conducted for melanoma, non-melanoma skin cancer, and lymphoma. The pooled hazard ratio (HR) for lymphoma was 1.00 (95% CI 0.40-2.53), for melanoma 0.80 (95% CI 0.27-2.34), and for non-melanoma skin cancer 0.38 (95% CI 0.00-732.76), suggesting no consistent associations.</p><p><strong>Conclusion: </strong>This meta-analysis did not identify significant differences in cancer risk across the examined subgroups. While a protective effect of vitiligo against some malignancies cannot be excluded, substantial heterogeneity among studies warrants cautious interpretation. Further high-quality research is needed to clarify these associations.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"3009-3024"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study.","authors":"Yukari Okubo, Yayoi Tada, Hidetoshi Takahashi, Masatoshi Abe, Keiichi Yamanaka, Nicola Tilt, Nancy Cross, Delphine Deherder, Mizuho Matano, Hidemi Nakagawa","doi":"10.1007/s13555-025-01509-9","DOIUrl":"10.1007/s13555-025-01509-9","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to report bimekizumab (BKZ) efficacy and safety in Japanese patients with generalised pustular psoriasis (GPP) and erythrodermic psoriasis (EP).</p><p><strong>Methods: </strong>Patients aged ≥ 18 years with plaque psoriasis, GPP, or EP received BKZ for 144 weeks; only results for GPP and EP reported here. All patients received BKZ 320 mg every 4 weeks (Q4W) at week 0, with dose adjustments for Q4W or Q8W at weeks 16 and 48, depending on Investigator's Global Assessment (IGA) 0/1 response. Efficacy outcomes assessed to week 144: IGA 0/1, Dermatology Life Quality Index (DLQI) 0/1, Clinical Global Impressions-Improvement (CGI-I), ≥ 75/90/100% improvement from baseline Psoriasis Area and Severity Index (PASI 75/90/100), ≥ 75/90/100% improvement from baseline modified Nail Psoriasis Severity Index (mNAPSI 75/90/100), and patient-reported outcomes; GPP-specific outcomes: Japanese Dermatological Association (JDA) severity index and Global Improvement Score (GIS). Treatment emergent adverse events (TEAEs) evaluated through weeks 0-144 and safety follow-up.</p><p><strong>Results: </strong>At week 144, most patients with GPP (8/10) and EP (10/11) completed the study. At week 16, all patients reported efficacy outcomes improving with BKZ, generally persisting through week 144. At week 144 (missing visit: 1 GPP), 6/7 patients with GPP and 8/10 with EP achieved IGA 0/1; 5/7 and 9/10 patients achieved DLQI 0/1; 7/7 and 9/10 patients achieved CGI-I response (\"improved\"/\"remission\"); and 6/7 and 9/10 patients achieved PASI 90, respectively; 2/5 patients with GPP and 4/9 with EP achieved week 144 mNAPSI 100. Among patients with GPP, JDA severity index generally decreased and improvements in GIS were sustained to week 144. Serious TEAEs were observed in 2/10 patients with GPP and 5/11 with EP; BKZ was well tolerated with low incidence of TEAEs leading to study discontinuation (2 GPP, 1 EP).</p><p><strong>Conclusions: </strong>Long-term BKZ treatment over 3 years improved signs and symptoms of GPP and EP; these were sustained through week 144. No new safety signals were identified.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, NCT03598790.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2947-2966"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis of Gene Expression Reveals the Core Transcriptomic Profile of Lesional Scalp in Alopecia Areata.","authors":"Irene Rivera-Ruiz, Jesús Gay-Mimbrera, Pedro J Gómez-Arias, Macarena Aguilar-Luque, Miguel Juan-Cencerrado, Carmen Mochón-Jiménez, Esmeralda Parra-Peralbo, Beatriz Isla-Tejera, Francisco Gómez-García, Juan Ruano","doi":"10.1007/s13555-025-01471-6","DOIUrl":"10.1007/s13555-025-01471-6","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata (AA) is an immune-mediated inflammatory skin disease that targets hair follicles. Current research yields varied lists of differentially expressed genes (DEGs). A meta-analytic approach is essential to consolidate these findings into a consistent tissue signature. This study aimed to perform a meta-analysis of gene expression datasets to establish a comprehensive molecular signature of AA lesional scalp.</p><p><strong>Methods: </strong>We conducted a meta-analysis of transcriptomic data from human studies on lesional skin gene expression in AA. Reanalyzing 132 samples (82 patients with AA and 50 controls) from five Gene Expression Omnibus (GEO) datasets (GSE68801, GSE45512, GSE80342, GSE58573, GSE74761), we employed an effect size approach within a random-effects model to identify unique and shared DEGs and enriched biological pathways. The protocol is registered in PROSPERO (CRD42024559847).</p><p><strong>Results: </strong>The meta-analysis identified 5109 DEGs, with 2710 upregulated and 2399 downregulated genes, significantly more than the 120 DEGs shared across the five studies. Consistently expressed genes included CXCL9, CCL18, CXCL10, CD8A, and GZMB (FDR < 0.05). The analysis highlighted chemokines/receptors (CCL13, CCR1, XCL1) and markers of cytotoxic T lymphocytes (GZMA, GZMH, GZMK) and NK cells (NKG2A, NKG2D). Downregulated genes involved type I (KRT31-35, KRT38) and type II (KRT81-86) keratins and proteins crucial for hair follicle structure and function (PADI3, GPRC5D, DSG4, FGF18). Functional analysis showed enrichment in Th1, Th2, and Th17 pathways, particularly through JAK-STAT signaling (p < 0.01).</p><p><strong>Conclusion: </strong>This core transcriptome of AA lesions provides new insights into the disease's pathogenesis and identifies potential targets for treatment.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2729-2748"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of 5-Fluorouracil 4% Cream in the Treatment of Hyperkeratotic Actinic Keratosis: A Single-Center Retrospective Real-World Study.","authors":"Federica Li Pomi, Andrea d'Aloja, Marta Vitale, Michelangelo Rottura, Natasha Irrera, Mario Vaccaro, Francesco Borgia","doi":"10.1007/s13555-025-01518-8","DOIUrl":"10.1007/s13555-025-01518-8","url":null,"abstract":"<p><strong>Introduction: </strong>Actinic keratosis (AK) is recognized as the main precursor of cutaneous squamous cell carcinoma (cSCC). Given the unpredictable potential for progression, current guidelines recommend treating all AKs, irrespective of their clinical grade. However, many approved treatments are not indicated for hyperkeratotic AKs. Among topical therapies, 5-fluorouracil (5-FU) 4% cream (Tolak®/Tolerak®; Pierre Fabre) is a chemotherapeutic agent that has shown excellent results in treating non-hyperkeratotic AKs on the face, ear, and scalp, both in clinical trials and real-life experiences. However, its effectiveness in managing hyperkeratotic AKs remains unexplored.</p><p><strong>Methods: </strong>A retrospective, single-center study was conducted at the Dermatology Unit of the University of Messina, Italy, between September 2024 and March 2025. The study included 66 hyperkeratotic AK lesions in 19 consecutive patients, treated with 5-FU cream for 28 consecutive days.</p><p><strong>Results: </strong>At the 3-month follow-up, total clearance (complete lesion resolution) was observed in 54.5% of hyperkeratotic lesions, while partial clearance (> 75% lesion reduction) was recorded in 24.2%. The treatment demonstrated a good safety profile, with good patient tolerability. Among local skin reactions (LSRs), erythema was the most frequently observed, occurring in 89.5% of patients, followed by stinging, which was reported in 73.6% of cases. No patient discontinued the treatment as a result of the onset of adverse events.</p><p><strong>Conclusions: </strong>Our findings, albeit initial, support the efficacy and safety of 5-FU 4% cream for the treatment of hyperkeratotic AKs.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2997-3007"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding: \"Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta‑Analysis\".","authors":"Tiago Torres, Luis Puig","doi":"10.1007/s13555-025-01513-z","DOIUrl":"10.1007/s13555-025-01513-z","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"3065-3068"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching from Dupilumab to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Podcast Article.","authors":"Vivian Y Shi, Erman Güler, Brian Esparza, Jonathan I Silverberg","doi":"10.1007/s13555-025-01491-2","DOIUrl":"10.1007/s13555-025-01491-2","url":null,"abstract":"<p><p>As the number of systemic agents available for the treatment of moderate-to-severe atopic dermatitis (AD) continues to increase, it is likely that patients may need or want to switch from one treatment to another. Owing to differences in the mechanism of action, the systemic agents abrocitinib (an oral Janus kinase 1-selective inhibitor) and dupilumab (an injectable interleukin 4 alpha antagonist) are associated with distinct efficacy and safety profiles. Two recent publications have examined the efficacy and safety of long-term abrocitinib in patients previously treated with dupilumab. In this podcast article, two dermatologists discuss the management of moderate-to-severe AD and highlight factors to consider before changing therapies in the context of these recent studies, focusing on switching from dupilumab to abrocitinib treatment.Below is the link to the electronic supplementary material. Supplementary file1 (MP4 173881 KB).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2703-2714"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}